Neurocrine Biosciences Preliminary Full-Year INGREZZA Net Product Sales Up 32%

Neurocrine Biosciences, Inc. (NBIX) said, based on preliminary unaudited financial information, the company expects INGREZZA net product sales for the three months and full-year ended December 31, 2020 to be approximately $240 million and $993 million respectively. INGREZZA inventory adjusted net product sales for the fourth quarter were approximately $258 million. Full-year 2020 total INGREZZA prescriptions grew 32% to approximately 175,700.

The company said it plans to provide clinical data for key programs and expects to begin seven additional mid-to-late stage clinical studies in 2021 for neurological, endocrine and psychiatric disorders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million...
Follow RTT